Riskpilot← Back to searchSign inGet full accessXIXON AB
ABActiveOrg 5568647670Hinsnoret 47General medical practice activities · NACE 8621Est. 20111 employees
Revenue 2025
SEK 18K
0% vs 2024
EBITDA margin
-411.1%
+11% vs 2024
Equity ratio
70.2%
Financial strength
Net profit 2025
SEK 1M
-4% vs 2024
| Revenue | SEK 18K | +0% |
| EBITDA | SEK -74K | +11% |
| Net profit | SEK 1M | -4% |
| Total assets | SEK 7,1M | +12% |
| Equity | SEK 5M | +18% |
| Employees | 1 | — |
Legal name
XIXON AB
Org number
5568647670
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
16 september 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva tillverkning och försäljning av medicinska produkter, medicinsk konsultverksamhet, utbildning inom sjuk- och hälsoområdet samt därmed förenlig verksamhet.
Address
Hinsnoret 47
Email
hallen.junquera@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 197 | 99 | 18 | 18 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −81 | 89 | 1 | −83 | −74 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −81 | 89 | 1 | −83 | −74 |
| Net financials | 593 | 1 313 | 1 907 | 1 715 | 1 693 |
| Profit before tax | 388 | 1 053 | 1 589 | 1 362 | 1 323 |
| Tax | −86 | −223 | −338 | −298 | −304 |
| Net profit | 302 | 830 | 1 251 | 1 064 | 1 019 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 712 | 3 872 | 5 478 | 6 349 | 7 133 |
| Equity | 1 846 | 2 496 | 3 567 | 4 231 | 5 009 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 11 | 171 | 387 | 323 | 33 |
| Total debt | 11 | 171 | 387 | 323 | 33 |
EBITDA margin
-411.1%
This company
15.8%
Market median
-2702% vs market
20212025
Equity ratio
70.2%
This company
38.2%
Market median
+84% vs market
20212025
Return on equity
20.3%
This company
18.4%
Market median
+10% vs market
20212025
Net profit margin
5661.1%
This company
8.1%
Market median
+69790% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LD Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
PM Audit | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of XIXON AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Mikael Runsvik | Audit | 0 companies |
| Lars Desta Hallén | Chief Executive Officer | 0 companies |
| Maria Luisa Fernandez Junquera | Deputy Board Member | 0 companies |